Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eribaxaban SCHEMBL17294640 | 1.00 | F10 (1.00) | F10 | |
| Eribaxaban SCHEMBL16436969 | 1.00 | F10 (1.00) | F10 | |
| SCHEMBL3832117 | 0.91 | F10 (0.84) | F10 | |
| SCHEMBL3834852 | 0.91 | F10 (0.84) | F10 | |
| SCHEMBL3835382 | 0.91 | F10 (0.84) | F10 | |
| SCHEMBL8273153 | 0.91 | F10 (0.84) | F10 | |
| SCHEMBL3832111 | 0.90 | F10 (0.82) | F10 | |
| SCHEMBL3835174 | 0.90 | F10 (0.82) | F10 | |
| SCHEMBL3828719 | 0.90 | F10 (0.81) | F10 | |
| SCHEMBL3833371 | 0.90 | F10 (0.81) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 408 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605371-B2 | Combination therapy for cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-04-21 | — | — | US | claimed |
| US-20260083773-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | EPIZON PHARMA INC (US) | 2026-03-26 | — | — | US | claimed |
| US-12521258-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-12514871-B2 | Pegylated menaquinol compositions and methods of treatment | Epizon Pharma, Inc. (US) | 2026-01-06 | — | — | US | claimed |
| WO-2025132678-A1 | QUALITATIVE TEST FOR DIRECT ORAL ANTICOAGULANTS (DOACS) | F. HOFFMANN-LA ROCHE AG (CH) | 2025-06-26 | — | — | WO | claimed |
| US-20250186563-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2025-06-12 | — | — | US | claimed |
| CN-120060160-A | Escherichia coli phage and application thereof | 杭州诺安百汇医药科技有限公司 | 2025-05-30 | — | — | CN | claimed |
| EP-3604510-B1 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2025-03-26 | — | — | EP | claimed |
| US-20250092380-A1 | ANTIDOTES TO FACTOR XA INHIBITORS | ALEXION PHARMA INC (US) | 2025-03-20 | — | — | US | claimed |
| EP-4493183-A2 | TRANSDERMAL DELIVERY SYSTEMS FOR CERTAIN FACTOR XA INHIBITORS AND RELATED METHODS FOR THEIR PREPARATION AND USE | Arx, LLC (US) | 2025-01-22 | — | — | EP | claimed |
| WO-2022031758-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR PULMONARY USE | ELIXIR MEDICAL CORPORATION (US) | 2022-02-10 | — | — | WO | claimed |
| US-20220039976-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2022-02-10 | — | — | US | claimed |
| WO-2022026398-A1 | COMBINATION THERAPY FOR CANCER | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-02-03 | — | — | WO | claimed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | claimed |
| US-20090221546-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | PFIZER INC | 2009-09-03 | — | — | US | claimed |
| US-7407974-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | PFIZER INC. (US) | 2008-08-05 | — | — | US | claimed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | claimed |
| US-20060183739-A1 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2006-08-17 | — | — | US | claimed |
| US-7030141-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2006-04-18 | — | — | US | claimed |
| EP-1465864-B1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER LAMBERT CO (US) | 2006-03-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092380-A1 | ANTIDOTES TO FACTOR XA INHIBITORS | SERPINC1, F2, F8 | F10 6/4885 |
| US-20250186563-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | SERPINC1, F8, F9 | F10 6/4885 |
| US-20100256131-A1 | CARBONYL COMPOUNDS | F2, F11, PDHX | F10 5/4885 |
| US-20090221546-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | F11, F2, TFPI | F10 10/4885 |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | F2, PDHX, SDHB | F10 22/4885 |
| US-20060183739-A1 | Carbonyl compounds | F2, F11, PDHX | F10 5/4885 |
| US-20260083773-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | SGMS1, SGMS2, MEN1 | F10 1095/4885 |
| US-12605371-B2 | Combination therapy for cancer | BRAF, TFPI, HGFAC | F10 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.